CenterWatch Monthly September 2008 Issue
Central and Eastern Europe: Growth Opportunities, Growing Pains
Given the uneven length of global clinical trial experience in CEE countries, many industry insiders consider that the region has both emerging and “emerged” countries. Growth is expected to continue generally in the CEE region, perhaps more quickly in the largest countries, such as Russia and Ukraine. CRO opportunities are many in Central and Eastern Europe. Global CROs made three major acquisitions between the end of October 2007 and mid April 2008, and that trend should continue. More protocols in the major centers are driving increased competition for sites and clinical research personnel and pushing CROs outside metropolitan research centers to more regional sites.
No Fazing Phase I Growth
Phase I studies have become more complex as drug sponsors want critical data about their compounds to help inform decision-making and avoid expensive late-phase failures. For CROs that offer early phase services, the future looks good. Demand for outsourced phase I work is increasing at a 13% to 15% rate, slightly higher than the 12% growth rate reported last year.
CRAcademy Offers New CRA Training Model in Europe
As most industry insiders will acknowledge, the clinical research employment market has undergone a shift—on a global scale—from being employer-driven to candidate-driven. Difficulties finding and keeping qualified clinical trials personnel in Europe and elsewhere have grown. Observers agree that the available workforce simply isn’t large enough to meet staffing needs. Experienced and inexperienced professionals alike are capitalizing on the clinical research industry’s staffing shortfalls.
Eye On: Allergies
Allergic reactions are defined as abnormal, excessive responses of the immune system in response to an otherwise harmless, foreign protein known as an allergen. Individuals who are genetically predisposed to a specific allergy or to multiple allergies mount an immune response via lymphocytes, immunoglobulin E (IgE) antibodies, inflammatory mediators and mast cells. This results in symptoms involving the target organs, namely, the nose, eyes, bronchial tubes, skin and gastrointestinal tract.
To read the full articles for this issue or for more information on these and other breaking stories, please click here.